Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trialS Peters, E Felip, U Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)|August 1, 2025
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer groupE Xenophontos, N Giaj Levra, V Durieux, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 24, 2020
Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European expertsP M Putora, G F Fischer, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2021
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trialS Peters, J-L Pujol, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2025
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitorsE S M van Aken, B Devnani, A Prelaj, et al.
ESMO Open|February 27, 2026
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitorsE S M van Aken, S M O'Cathail, A K Gandhi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2026
ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumoursK S Saini, M Koopman, D Martins-Branco, et al.
Pageof 6